PD-1/L1 competition is heating up in the new battleground of kidney cancer, as Merck & Co. Inc. announced its Keytruda (pembrolizumab) in combination with Pfizer Inc.’s tyrosine kinase inhibitor Inlyta (axitinib) has hit both overall and progression-free survival endpoints in the Phase III KEYNOTE-426 study in first-line advanced/metastatic renal cell carcinoma.
An interim analysis has revealed statistically significant and clinically meaningful improvements in OS and PFS, compared to sunitinib monotherapy, with the Keytruda plus Inlyta combination, Merck & Co. announced Oct....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?